ERBB2 and cancer: have proposed an approach by simultaneously delivering miR‐21 inhibitor and 5‐FU to HER2+ cancer cells via exosomes, which apparently enhances their sensitivity to 5‐FU.[278] Similarly, Bose et al. suggest that cancer cell‐derived EVs loaded with miR‐21 inhibitor can block the function of endogenous oncogenic miR‐21 and significantly reduce the resistance of breast cancer cells to DOX.[279]